Rivaroxaban versus warfarin in Chinese elder diabetic patients with non-valvular atrial fibrillation: A retrospective study on the effectiveness and associated risks (EAR) analysis
Purpose: To evaluate the effectiveness and associated risks of rivaroxaban against warfarin in Chinese elderly diabetic patients with non-valvular atrial fibrillation.
Methods: Data regarding demographical characteristics, clinical conditions, ischemic stroke, intracranial bleeding, gastrointestinal tract bleeding, myocardial infractions, hip/pelvic fracture, asthma, breast/prostate cancer, and death during 3-years of treatment of 584 Chinese diabetic patients with confirmed non-valvular atrial fibrillation who were placed on rivaroxaban (RX Cohort, n = 201) or warfarin (WF Cohort, n = 383) were collected from hospital records and analyzed. Multivariate analysis was performed for the prediction of the incidence of the treatment-emergent event(s).
Results: During the 3-year treatment period, higher numbers of patients were reported for intracranial bleeding (p = 0.042), ischemic stroke (p = 0.042), gastrointestinal bleeding (p = 0.0006), hip/pelvic fracture (p = 0.042), and asthma (p = 0.0007) in WF cohort than RX cohort. Also, higher mortality was reported in WF cohort than for RX cohort (24 vs. 4, p = 0.024). Female sex (p = 0.031), age (p = 0.035), and comorbidities (p = 0.021) were associated with incidence of treatment-emergent event(s).
Conclusion: With rivaroxaban, a significant and safe risk-reduction of thromboembolic events are found in elderly diabetic patients with non-valvular atrial fibrillation.
Keywords: Anticoagulant, Diabetes, Non-valvular atrial fibrillation, Rivaroxaban, Warfarin
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.